Assessment of the safety and immunogenicity of the Covid-19 candidate vaccine developed by Vabiotech in Golden Syrian hamster

Abstract

The study was conducted to evaluate the safety and immunogenicity in 8 the golden  Syrian hamster model of the candidate  vaccine against Covid-19 (COVINVAX) developed by VABIOTECH. Healthy mice after vaccination, did not show any disease, created a good immune response after 2 injections of vaccine intramuscularly in both neutralizing immune response (PRNT₅₀) GMT PRNT50 day 35 in 5 mcg and 10 mcg vaccines groups were: 100.8; 320, humoral immunity (IgG antibody concentration) with GMT day 35 in 2 groups were: 22.8; 84.6, IgG/IgM anti-S-protein against SARS-CoV-2) and a dominant immune response to Th1 with IgG2/IgG3 of 2015.9, IgG1 of 315.5 (Th2 polarized responses). Immune response was highest in the groups of mice injected intramuscularly with 2 doses of 10mcg vaccine. Therefore, the COVINVAX vaccine achieved safety and immunogenicity requirements in the golden Syrian hamster model, which is the basis for further study challenge and in larger animal models and human clinical trials.